Comparative Pharmacokinetics and Bioequivalence Assessment of Vonoprazan Fumarate Tablet in Fasting and Fed Conditions: A Randomized Study in Healthy Chinese Subjects
Clinical Pharmacology in Drug Development · 2026-11 · 15 (11)
DOI: 10.1002/cpdd.70128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 20.11.2026. Verfasst von Hongcheng Li und 6 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
This study evaluated the bioequivalence and safety of test formulation of vonoprazan fumarate tablet versus the reference formulation VOQUEZNA (Takeda Pharmaceuticals) in healthy Chinese subjects under fasting and fed conditions. Vonoprazan fumarate is a novel potassium‐competitive acid blocker that inhibits gastric acid secretion via H + /K + ‐ATPase inhibition. This is a randomized, open‐label, single‐dose, two‐formulation, two‐period, two‐sequence crossover study conducted with 28 subjects under fasting conditions and 40 under fed conditions. Participants were randomized 1:1 to receive either the test or reference formulation, followed by a 7‐day washout period before crossover. Blood samples were collected up to 48 h post‐dose. Concentrations of vonoprazan in plasma were quantified using a validated LC‐MS/MS method. Pharmacokinetic (PK) parameters (C max , AUC 0–t , and AUC 0–∞ ) were derived via non‐compartmental analysis. In both studies, bioequivalence was determined if 90% confidence intervals (CIs) for geometric mean ratios (GMRs) fell within 0.80–1.25. Safety was monitored throughout the study. Under fasting conditions, GMRs (test/reference) of C max , AUC 0–t , and AUC 0–∞ were 0.96, 1.03, and 1.03, respectively. Under the fed condition, GMRs were 0.93, 0.99, and 0.99, respectively. The 90% confidence intervals for these parameters were within the 0.80–1.25 bioequivalence acceptance range. Both formulations exhibited comparable safety profiles, with no serious adverse events reported. The test and reference formulations demonstrated PK bioequivalence under fasting and fed conditions, satisfying regulatory requirements. Both formulations were safe and well tolerated. Trial Registration : Chinese Clinical Trial Register: CTR20243703
Zitieren
APA
Li, H., Wang, F., Huang, Y., Cai, H., Zhang, J., Liu, B., & Li, X. (2026). Comparative Pharmacokinetics and Bioequivalence Assessment of Vonoprazan Fumarate Tablet in Fasting and Fed Conditions: A Randomized Study in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development, 15(11). https://doi.org/10.1002/cpdd.70128
Vancouver
Li H, Wang F, Huang Y, Cai H, Zhang J, Liu B, et al. Comparative Pharmacokinetics and Bioequivalence Assessment of Vonoprazan Fumarate Tablet in Fasting and Fed Conditions: A Randomized Study in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2026;15(11). doi:10.1002/cpdd.70128
BibTeX
@article{Li2026,
author = {Li, Hongcheng and Wang, Fuzhou and Huang, Yanan and Cai, Hongdan and Zhang, Jingshu and Liu, Bin and Li, Xiaohui},
title = {Comparative Pharmacokinetics and Bioequivalence Assessment of Vonoprazan Fumarate Tablet in Fasting and Fed Conditions: A Randomized Study in Healthy Chinese Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cpdd.70128}
}
EUVIMED